How to reconstitute GHRP-2: mixing and storage
A peptide that releases growth hormone and can increase hunger.
Also called: Pralmorelin, KP-102, GPA-748.
Growth hormone secretagogues (ghrelin receptor) · Ghrelin receptor agonist and growth hormone secretagogue.
Comes as: Lyophilized powder in community vials, Japanese 100 mcg diagnostic vial, Nasal spray and oral preparations studied separately.
Mixed with: Community replies use bacteriostatic water. The Japanese diagnostic vial uses 10 mL saline immediately before IV use..
Common vial sizes: 5 mg. Common water amounts: 2.5 mL.
- The 5 mg/2.5 mL example is community-reported, not the Japanese diagnostic formulation.
- The Japanese product is kept below 10°C without freezing and protected from light; use promptly after mixing.
- Japanese label stability information cannot be transferred to unknown community formulations.
Before mixing: Community users refrigerate vials; no validated shelf life for unregulated products was found.
After mixing: Users refrigerate mixed vials. No general home-vial beyond-use period is established.
Related to GHRP-2
- Ipamorelin: An experimental peptide that triggers growth hormone release.
- MK-677 (ibutamoren): This experimental oral drug raises growth hormone and IGF-1; risks include high blood sugar and swelling.
- GHRP-6: A peptide studied in growth hormone tests and an experimental stroke combination.
- Hexarelin: A peptide that releases growth hormone; repeated use can weaken the response.
- BPC-157: An experimental repair peptide with mostly animal evidence and a few small human reports.
- Sermorelin: An experimental short-acting peptide that triggers growth hormone release, with limited evidence of adult benefits.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, FDA · FDA · 2026
- Find product information about medicines, Medicines and Healthcare products Regulatory Agency · MHRA · 2026
- Peptide products, Therapeutic Goods Administration · TGA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- GENOTROPIN® (somatropin) for injection, for subcutaneous use, FDA · 2025
- 注射用GHRP科研100, PMDA · 2025
- October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee, FDA · 2024
- Using intramuscular injections in people on oral anticoagulants, NHS Specialist Pharmacy Service · NHS Specialist Pharmacy Service · 2023
- Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline., Molitch ME et al. · The Journal of clinical endocrinology and metabolism · 2011
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.